Work

Supplementary Table S1 from Phase II study of docetaxel and trametinib in patients with KRAS mutation positive recurrent non-small cell lung cancer (NSCLC) (SWOG S1507, NCT-02642042)

Year: 2024

Type: supplementary-materials

Abstract: Supplementary Table 1. Dose Modifications for Docetaxel and Trametinib

DOI: 10.1158/1078-0432.27031963.v1

Authors: Shirish M. Gadgeel, Jieling Miao, Jonathan W. Riess, James Moon, Philip C. Mack, Gregory J. Gerstner, Timothy F. Burns, Asma Taj, Wallace L. Akerley, Konstantin H. Dragnev, Noel Laudi, Mary W. Redman, Jhanelle E. Gray, David R. Gandara, Karen Kelly

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4402800308

Cites:

Cited by:

Related to: 10